BioAge Labs Inc

BioAmber, Inc. is an industrial biotechnology company, which produces sustainable chemicals. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in everyday products, including plastics, resins, paints, food additives and personal care products. The firm's products include bio-based succinic acid, butanediol and bio-based disodium succinate. The company was founded on October 15, 2008 and is headquartered in Montreal, Canada.

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

ATTENTION BIOA SHAREHOLDERS: Investors who lost money on BioAge Labs, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA INVESTIGATION ALERT: An Investigation is Pending into BioAge Labs after the Stock Dropped 76% - Contact BFA Law if You Suffered Losses

NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details

BioAge Labs, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - BIOA

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

BioAge Labs, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Encourages Stockholder Participation

BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - BIOA

Did BioAge Labs, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- BIOA

NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA INVESTOR NOTICE: BioAge Labs is being Investigated after Discontinuing its Phase 2 Trials -- Contact BFA Law (NASDAQ:BIOA)

NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

ATTENTION BioAge Labs, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against BioAge Labs, Inc. (BIOA) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESSWIRE / December 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

BioAge Labs, Inc. (BIOA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses.

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA SHAREHOLDER NEWS: BioAge Labs, Inc. Investors are Notified of the Ongoing Investigation into the Discontinuation of the Phase 2 Trials – Contact BFA Law

LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses Are Invited To Join The Schall Law Firm's Inquiry Into BioAge Labs Inc For Securities Fraud

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

Bronstein, Gewirtz & Grossman, LLC Is Investigating BioAge Labs, Inc. (BIOA) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.

Investors who lost money on BioAge Labs, Inc. should contact Levi & Korsinsky about an ongoing investigation - BIOA

LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

BioAge Labs Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Encourages Shareholder Participation

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA SHAREHOLDER NEWS: BioAge Labs is being Investigated after Stock Drops 76% - Contact BFA Law if You Suffered Losses

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

BioAge Labs, Inc. (BIOA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

BioAge Labs, Inc. (BIOA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ: BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA INVESTIGATION ALERT: BFA Law Alerts BioAge Labs, Inc. Investors of its Ongoing Investigation – Contact the Firm if You Incurred Losses (NASDAQ:BIOA)

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential violations of the federal securities laws. If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.

BIOA INVESTIGATION NEWS: BioAge Labs, Inc. Stock Plummets 76% - Investors are Urged to Contact BFA Law about its Investigation

LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors With Losses Are Invited To Join The Schall Law Firm's Inquiry Into BioAge Labs, Inc. For Securities Fraud

ATLANTA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) complied with federal securities laws. On December 6, 2024, BioAge announced the discontinuation of the Strides Phase 2 study of its investigational drug candidate azelaprag due to safety concerns “after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag.”  Following this news, the price of the Company's stock dropped.

SHAREHOLDER ALERT: Investigation of BioAge Labs, Inc. (BIOA) Announced by Holzer & Holzer, LLC

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioAge Labs, Inc. (BIOA) and Encourages Stockholders to Learn More About the Investigation

News for BioAge Labs Inc Stock (BIOA)